Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • Analyst Insights & IR
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Alteogen(196170) to List 170,300 Additional Common Shares Following Exercise of Stock Options

Posted on October 24, 2024July 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Alteogen(196170) to List 170,300 Additional Common Shares Following Exercise of Stock Options

Source Fact: Financial Supervisory Service DART / 2024-10-24

Disclosure Type: Additional Listing (Exercise of Stock Options)

💡 3-Second Summary

Alteogen will issue and list 170,300 additional common shares on October 29 following the exercise of employee stock options, with exercise prices ranging from a minimum of KRW 8,917 to a maximum of KRW 63,889 per share.

📊 1. [Summary of Core Disclosure Content and Major Figures]

  • Company Name: Alteogen Co., Ltd. (Ticker: 196170)
  • Type and Number of Additional Shares: 170,300 Common Shares
  • Par Value per Share: KRW 500
  • Reason for Additional Listing: Exercise of stock options (Exercise Date: October 16, 2024)
  • Detailed Issuance Breakdown:
    • 101st Round: 21,200 shares (Exercise Price: KRW 10,000)
    • 102nd Round: 60,000 shares (Exercise Price: KRW 8,917)
    • 103rd Round: 41,100 shares (Exercise Price: KRW 21,111)
    • 104th Round: 18,000 shares (Exercise Price: KRW 23,833)
    • 105th Round: 30,000 shares (Exercise Price: KRW 63,889)
  • Total Outstanding Shares Post-Listing: 53,318,828 Common Shares
  • Listing Date: October 29, 2024
  • Dividend Dividend Base Date: January 01, 2024

📈 2. [Expert View: What This Disclosure Means for Investors]

This filing announces an increase in capital stock resulting from the conversion of employee stock options into tradable equity. While the newly issued shares generate a modest cash inflow (approximately KRW 3.36B) into the company’s treasury, this action does not modify the structural business fundamental, such as revenue lines or biological pipeline progressions, and should be evaluated primarily as a short-term liquidity and supply event.

The potential risk factors that market participants should monitor involve share dilution and subsequent overhang pressures. The incoming 170,300 shares account for a very limited portion (approximately 0.32%) of the expanded outstanding capital stock (53,318,828 shares). However, because the preset exercise prices (KRW 8,917 to KRW 63,889) reside significantly below the prevailing market price at the disclosure timeline, option holders face compelling incentives to execute immediate profit-taking sales. Consequently, a practical approach requires investors to treat the listing date (October 29) and its immediate aftermath as a window of heightened short-term market volatility.

📝 Editor’s Comment (by K-STOCK Editor)

A batch of stock options held by Alteogen’s internal staff has officially been converted into shares, hitting the market on October 29. While the headline total of over 170,000 shares translates to just 0.32% of total floating equity, the core factor to emphasize is the deep discount on the exercise prices. With entry points fixed between KRW 8,917 and KRW 63,889, these shares hold enormous untaxed gains relative to current trading values. This valuation gap sets up a strong probability for immediate post-listing liquidation from the holders. Investors would be wise to tone down any short-term optimism and carefully map institutional and individual volume changes around the listing frame.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on the official data submitted to the Electronic Disclosure System (DART) of the Financial Supervisory Service.

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] SK hynix (000660) Destroys Q3 Earnings: Quarterly Operating Profit Crushes KRW 7T Milestone, Storming Back into Massive Profit YoY!
Next Post: [Disclosure] JUSUNG ENGINEERING (036930), Trading Suspension Confirmed for Single-Stock Futures on Oct 30 Coinciding with Demerger Schedule

Related Posts

[Disclosure] Alteogen (196170) to List 28,055 Additional Common Shares via Preferred Stock Conversion Disclosures
[Disclosure] Alteogen (196170) Scores Huge Win: Eylea Biosimilar ‘Eyzanfy’ Secures Official MFDS Marketing Approval in South Korea Disclosures
[Disclosure] Alteogen(196170) Reports KRW 114.7B Operating Profit for 2025… A Massive 274.8% YoY Surge Disclosures
[Disclosure] Alteogen(196170) Sets November 21 as Record Date for Extraordinary Shareholders’ Meeting Disclosures
[Disclosure] Alteogen(196170) Resolves to Convene Extraordinary Shareholders’ Meeting on Dec 8 for KOSPI Transfer Approval Disclosures
[Disclosure] Alteogen (196170) to List 40,820 Additional Common Shares Following Executive Stock Option Exercises Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hana Micron (067310) Lifted from Investment Warning Stock Status; Reclassified to Investment Caution on June 9 with Re-designation WarningJuly 8, 2026
  • [Discount Reversal via ADR Listing and Entry into an HBM-Led Super Cycle: SK hynix 000660]July 7, 2026
  • [Discount Narrowing via ADR Listing Momentum and Capital Allocation Diversification: SK Square 402340]July 7, 2026
  • Gaon Cable (000500): Structural Re-rating Driven by North American Infrastructure Expansion and AI Data Center Demand ShocksJuly 7, 2026
  • Hugel (145020): Passing the Trough with Q2 Earnings Surprise and Accelerated U.S. Direct Sales DeploymentJuly 7, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme